Article ; Online: Dabigatran Reversal With Idarucizumab Preceding Thrombolysis in an Octogenarian Patient with Chronic Kidney Disease and Acute Stroke: A Case Report.
2020 Volume 42, Issue 9, Page(s) 1840–1845
Abstract: Background and purpose: Reversing the effect of dabigatran among patients with atrial fibrillation is important to normalize coagulation profile among patients who develop serious hemorrhage from any source. However, such intervention always has the ... ...
| Abstract | Background and purpose: Reversing the effect of dabigatran among patients with atrial fibrillation is important to normalize coagulation profile among patients who develop serious hemorrhage from any source. However, such intervention always has the potential to cause a prothrombotic state. Among patients suspected of ischemic stroke, Idarucizumab, may be administered preceding thrombolysis. This is a considerable option when given during the critical phase of revascularization. Methods: We report the case of an 84-year old, male, banker, known hypertensive with chronic renal disease. He has non valvular atrial fibrillation receiving Dabigatran at 75 mg twice daily and presented with symptoms of right-sided weakness, right hemisensory loss, facial asymmetry, and slurring of speech equating to National Institute of Health Stroke Scale (NIHSS) of 5. After coming into the hospital for a suspected stroke, 3 hours and 25 minutes after symptoms, complete reversal of Dabigatran with Idarucizumab was administered and intravenous thrombolysis was initiated 271 minutes post ictus. There was immediate improvement of the right upper extremity weakness and dysarthria 30 minutes post infusion. At 13 days post ictus, the patient was discharged with minimal right central facial palsy and right arm drift (NIHSS 2). Brain CT scan post revascularization did not reveal any hemorrhage and anticoagulant Apixaban 2.5 mg twice daily was started and maintained thereafter. Brain Magnetic Resonance Angiogram (MRA) showed complete recanalization of the left proximal MCA after 52 days. Conclusion: Our case showed the effectiveness and safety of giving Idarucizumab followed by thrombolysis in Dabigatran-treated atrial fibrillation with ischemic stroke. Based on this case, the procedure can be performed in an elderly population with chronic kidney disease when administered close to the limit of threshold for thrombolysis. |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| MeSH term(s) | Administration, Intravenous ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antithrombins/administration & dosage ; Antithrombins/adverse effects ; Atrial Fibrillation/drug therapy ; Dabigatran/adverse effects ; Dabigatran/therapeutic use ; Humans ; Hypertension/drug therapy ; Male ; Renal Insufficiency, Chronic/drug therapy ; Stroke/drug therapy ; Thrombolytic Therapy/adverse effects ; Thrombolytic Therapy/methods | ||||||||||
| Chemical Substances | Antibodies, Monoclonal, Humanized ; Antithrombins ; idarucizumab (97RWB5S1U6) ; Dabigatran (I0VM4M70GC) | ||||||||||
| Language | English | ||||||||||
| Publishing date | 2020-08-07 | ||||||||||
| Publishing country | United States | ||||||||||
| Document type | Case Reports | ||||||||||
| ZDB-ID | 603113-4 | ||||||||||
| ISSN | 1879-114X ; 0149-2918 | ||||||||||
| ISSN (online) | 1879-114X | ||||||||||
| ISSN | 0149-2918 | ||||||||||
| DOI | 10.1016/j.clinthera.2020.07.006 | ||||||||||
| Shelf mark |
|
||||||||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 1435: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
|||
| Zs.MO 404: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.